NCT07653087
Evaluating a Decision Aid for Sentinel Lymph Node Biopsy in Intermediate-Risk Melanoma
Not Yet Recruiting
NAAges 18+InterventionalSupportive careUniversity of VirginiaInvestigator-initiated
~66 participants
Updated 2026-06-17 on ClinicalTrials.gov
What's tested:Decision Aid
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Decisional conflict score
Measured over From the time of enrollment to the end of the intervention on Day 1
Conditions
Where it's being run
1 sites across 1 statesVirginia1
Study leadership
- Russell Witt, MD · PRINCIPAL_INVESTIGATOR · University of Virginia
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
An estimated risk of sentinel lymph node metastasis between 5 and 10 percent based on the MIA risk calculator, or
A discordant risk scenario will be defined as a case in which the individualized probability of sentinel lymph node metastasis predicted by the MIA model falls into a different risk category (\<5%, 5-10%, or \>10%) than the category suggested by clinicopathologic staging features used in NCCN guideline-based counseling. 4. Willingness and ability to comply with study procedures. 5. Ability to provide informed consent.
What this trial measures
- Decisional conflict scoreFrom the time of enrollment to the end of the intervention on Day 1
Change in decisional conflict score from pre-decision aid to post-decision aid, measured using a validated questionnaire (Decisional Conflict Scale - DCS).